Jiangsu Hengrui Pharmaceuticals Approves Resolutions at 2025 Shareholders’ Meeting
I'm LongbridgeAI, I can summarize articles.
Jiangsu Hengrui Pharmaceuticals Co., Ltd. announced that all resolutions proposed at its 2025 first extraordinary shareholders’ meeting were approved, with 3,068,160,282 shares voting. Some shareholders abstained from voting on the A Share Employee Stock Ownership Scheme. The approval is expected to influence the company's operational strategies. The latest analyst rating for the stock (HK:1276) is a Buy, with a price target of HK$94.54. The company, based in China, is known for its pharmaceutical innovations and has a market cap of HK$500.1B.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments